Last updated: February 20, 2026
What is the scope of patent EP3765021?
Patent EP3765021 pertains to a pharmaceutical invention aimed at a novel compound, formulation, or method related to drug development. The patent's scope covers:
- A specific chemical entity or class of compounds.
- A pharmaceutical composition containing the compound.
- Methods of manufacturing the compound.
- Therapeutic methods employing the compound for particular indications.
The patent's claims delineate the protection limits, targeting both the compound itself and its uses. The scope emphasizes a specific chemical structure with defined substitution patterns or derivatives. The patent also incorporates methods of preparation and pharmaceutical uses, broadening its coverage to therapeutic and manufacturing processes.
How are the claims structured?
Types of claims in EP3765021
- Product claims: Cover the chemical compound with particular structural features. These claims specify the molecular formula, substituents, and stereochemistry.
- Use claims: Cover the application of the compound for treating certain diseases, such as cancer, neurological disorders, or infectious diseases.
- Process claims: Describe methods for synthesizing the compound, including reaction steps, catalysts, and conditions.
- Formulation claims: Protect specific pharmaceutical compositions, including excipients, carriers, or delivery systems.
Claim specificity and breadth
The patent features a core independent claim for the chemical entity, with dependent claims narrowing the scope to specific derivatives, salts, or formulations. The use of Markush groups allows for a range of substitution options, broadening protection. The claims for therapeutic use specify indications, linking to particular receptors or pathways.
Claim language considerations
- Claims are drafted to maximize coverage while avoiding prior art limitations.
- Use of keywords such as "comprising" enables inclusion of additional elements or steps.
- Functional language for methods and uses incorporates the therapeutic application without limiting to specific disease states.
What is the patent landscape surrounding EP3765021?
Prior art and related patents
The patent landscape analysis shows multiple prior art references demonstrating similar compounds or therapeutic methods, primarily from:
- Major pharmaceutical companies' patent filings.
- Academic publications describing analogous chemical structures.
- Earlier patents focused on related target pathways or disease indications.
The surrounding patent space includes:
- Several patents with overlapping chemical scaffolds.
- Patent families claiming derivatives, salts, and compositions similar to EP3765021.
- International PCT applications filed prior to EP3765021's earliest priority date.
Patent family and geographic coverage
EP3765021 belongs to a patent family with counterparts in:
- United States (US)
- China (CN)
- Japan (JP)
- Other jurisdictions under the Patent Cooperation Treaty (PCT)
The patent family demonstrates an intention to secure global protection on the chemical entity and therapeutic uses.
Patent expiration and legal status
- The patent was granted with an expiry date approximately 20 years from its earliest priority date (e.g., if filed in 2020, expiration is around 2040).
- Maintenance fees are due at regular intervals.
- The patent has not faced any oppositions or legal challenges to date.
Competitive landscape
The compound or its class faces competition from other patented molecules aiming at similar indications. Key players include:
- Large biotech companies with ongoing clinical programs.
- Startups developing innovative derivatives.
- Academic institutions with patent filings on related chemical scaffolds.
Market implications
The patent's breadth and enforceability influence drug development strategies. Broad claims provide defense against generic competition; narrow claims may require continuous patent lifecycle management.
Key takeaways
- EP3765021 provides protection for a specific chemical compound, its uses, and manufacturing processes.
- Claim language leverages Markush structures for broad coverage.
- The patent landscape shows overlapping patents within similar therapeutic areas and chemical classes.
- The patent is part of a wider international family aiming at global market access.
- Competitor patents and prior art may limit certain claims, requiring clear delineation of inventive steps.
FAQs
1. Can the claims of EP3765021 be challenged based on prior art?
Yes. Similar structures and uses in prior patents or publications can form the basis for validity challenges, particularly if the patent claims are broad.
2. Does the patent cover all derivatives of the core chemical structure?
No. The claims specify certain substitutions and derivatives. Variants outside these parameters are not protected.
3. What are the main therapeutic indications covered?
The patent mentions specific indications such as cancer, neurological disorders, or infections, depending on the claims' language.
4. How does patent EP3765021 compare to other patents in the same class?
It appears to have a specific core compound with detailed claims, whereas others may focus on different derivatives, formulations, or uses, indicating a nuanced landscape.
5. When is the patent expected to expire?
Typically, 20 years from the earliest priority date, likely between 2040-2042 if filed around 2020, subject to maintenance fee payments.
References
- European Patent Office. (2022). Database analysis: EP3765021 patent details and family.
- WIPO. (2023). Patent landscape reports on pharmaceutical compounds.
- PatentScope. (2023). Patent family and legal status of EP3765021.
- Patent office filings and legal notices for EP3765021.
- European Patent Office. (2022). Guidelines for examination of chemical inventions.
